Key result
Lowering triglycerides to ≤/dL is linked to lower major cardiovascular events in primary, but not secondary, prevention.
Why the study?
Does a reduction in triglyceride levels reduce the risk of major adverse cardiovascular events in patients with baseline TG ≥150 mg/dL?
Cohort
Yes
Does a reduction in triglyceride levels reduce the risk of major adverse cardiovascular events in patients with baseline TG ≥150 mg/dL?
Answers are grounded in this paper and cite their sources.
A reduction in triglyceride levels to ≤150 mg/dL is weakly associated with a reduced risk of MACE in primary prevention, but not in secondary prevention cohorts.
Background: Previous analyses have reported that low triglyceride (TG) levels were associated with a reduced risk of cardiovascular events in a primary prevention cohort. However, it remains unclear whether a reduction in TG levels directly contributes to cardiovascular risk reduction. Objective: To investigate whether a reduction in TG levels is associated with a decreased risk of cardiovascular events in primary and secondary prevention cohorts. Methods: This retrospective study was conducted with a nationwide health insurance claims database, with medical checkups between January 2005 and August 2020 in Japan. We included patients with baseline TG levels ≥150 mg/dL and classified them into primary or secondary prevention of cardiovascular events. TG levels at one year were used to stratify patients into four groups: low (≤100 mg/dL), normal (100-149 mg/dL), high (150-499 mg/dL), and very high (≥500 mg/dL). The primary outcome was major adverse cardiovascular events (MACE). Results: In the primary prevention cohort, a reduction TG levels to ≤150 mg/dL was significantly associated with a reduced risk of MACE. No significant association was observed in the secondary prevention cohort. In subgroup analyses stratified by LDL-C target achievement, patients with elevated LDL-C showed a trend toward lower event risk with decreasing TG levels. Conclusion: A weak association was found between a reduction in TG levels and a reduced risk of cardiovascular events in the primary prevention population. However, prospective, randomized, placebo-controlled, and large cardiovascular outcomes trials are needed to prove that substantial reductions in TG levels correlate with cardiovascular event risk reduction.
No takes yet. Share an insight, caveat, or question.
Ishii et al. (2025) conducted a cohort in Cardiovascular events. Reduction in triglyceride levels vs. Higher triglyceride levels was evaluated on major adverse cardiovascular events (MACE). A reduction in triglyceride levels to ≤/dL was associated with a reduced risk of major cardiovascular events in the primary prevention cohort, but not in the secondary prevention cohort.
Synapse has enriched 10 related papers. Consider them for comparative context: